Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
about
Minimal Residual Disease Eradication in CML: Does It Really Matter?Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.Pathways to Genome-targeted Therapies in Serous Ovarian Cancer.Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment.Treatment-free remission in patients with chronic myeloid leukemia.Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.Defining the target and the effect of imatinib on the filarial c-Abl homologue.Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.An overview of the role of platelets in angiogenesis, apoptosis and autophagy in chronic myeloid leukaemia.Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment.QnAs with Tony Hunter and James Allison.Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis.Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase.Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma.The rocky road to personalized medicine in acute myeloid leukaemia.Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients.Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia.Revisiting the need for bone marrow examination in chronic myeloid leukemia.Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.Targeting tumour microenvironment by tyrosine kinase inhibitor.Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors.Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib.PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15- cells in early chronic-phase chronic myeloid leukemia.Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study.Understanding cancer from the stem cells up.Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.First person: Brian Druker, MD.
P2860
Q38602633-4C132171-EC88-4836-85B9-3466CF150224Q38609730-A355A558-DC03-4373-9B03-82A3012D850BQ38621094-3325BD3E-8D7E-4DD9-B1E6-75C2B7B9C448Q38681424-1EC7AE8D-F990-483B-86AE-6856817EE2D9Q39423384-13C6DE56-AAA3-443F-A85B-EAAEA6B10B71Q39457369-11A7380C-EB1E-4A94-AAD1-E64F76B2DA1BQ40126435-6EA92FB8-187B-4D54-B139-E7A115F8215AQ40996798-DA841A32-32F1-4E99-89F6-4D4F5D3B482AQ41348012-19E0D48E-EC27-49DA-A8E0-0483A42F29FFQ43235803-8EAB1041-0650-4FE5-9133-2EEDD71F1DDAQ45304786-37A49275-D274-4757-8DB5-6DCDC815CB34Q47096076-9576796E-BA90-42DD-835F-2C907E9414B9Q47135575-42AE61BC-3C0E-4F9F-A4B8-A9A7E663DDD8Q47141967-B73679EC-BA4F-4378-A311-93126FE57CD6Q47150923-F1AD461C-B0FD-402C-94D9-766F8DE901F7Q47162677-56445F09-4A7C-4E5F-97E2-49BBB185D05EQ47300241-6048053D-106F-4C1F-B49A-7929AD0FD0F8Q47393395-584CFEF5-66EB-42B1-B232-A87A4B3FB164Q47561008-4D23ED8C-ADE4-4D27-A400-8140A5BE74EAQ47760026-0D78C0BC-E787-4DB6-9E42-0AF2175CA83DQ47767989-226D448D-48EB-41B5-85B3-19FC9B608605Q47877989-252A27FB-0457-411C-9116-FD82F91A49A1Q47917650-8688237E-BDFF-4736-AD8B-CF9253A24011Q48109003-FAC7EA25-DE1D-4615-AC39-C0970C5769CDQ48154526-C14791F2-D9ED-4D77-AFCA-3B0A7FC0520AQ48193546-A8DE09F2-626F-44A6-A451-811472708A3FQ48320624-0A715C7B-B869-460B-8C7A-89A20F351AFCQ49833785-2BEC6666-7F1A-4512-B86E-20CBF3093ACDQ49887884-5FA88FC0-209C-4B02-AC6A-8DD082AC6DDDQ49887906-975D8CCD-A42C-4567-AC79-3ED993E01E30Q49988426-B14D66FD-4856-45C4-98FC-6B7D0BD122C6Q50284187-E53C9F6F-11ED-4175-A99B-1F7EA24444D0Q52430614-8159F299-722E-47CD-9737-36A15992374AQ52567954-AA866FCD-79EF-4AB4-A66A-3DDB3150D1ACQ52633239-4D3002E7-B335-407E-983F-CE5620A0076AQ52659302-E706B659-A200-47D8-9BFE-B25765ABD81EQ52766551-76671482-FAC7-40B2-8112-3C7386510D28Q52816089-65291210-80A5-4AAE-BE71-33F9B6EDB2F6Q53077187-2CD76C3D-DC3C-42EA-8940-0FBF6E25B6A2Q53311417-A18945D5-EE9B-4F80-B4E0-BE2F6E64E3A8
P2860
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
@en
type
label
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
@en
prefLabel
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
@en
P2093
P2860
P50
P356
P1476
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
@en
P2093
Brian J Druker
Christine-Elke Ortmann
Francisco Cervantes
Hans D Menssen
IRIS Investigators
Jerald P Radich
Michael W Deininger
Richard A Larson
Satoko Fujihara
Stephen G O'Brien
P2860
P304
P356
10.1056/NEJMOA1609324
P407
P577
2017-03-01T00:00:00Z